Skip to main content
. Author manuscript; available in PMC: 2020 Jan 8.
Published in final edited form as: Immunity. 2018 Mar 20;48(3):417–433. doi: 10.1016/j.immuni.2018.03.007

Table 1.

Strategies to restore PRR signaling

Target Examples under clinical investigation ± ICB References
PRR activation Chemotherapy Galluzzi et al, 2015
Radiation Shabason and Minn, 2017
HER2-directed antibody Park et al, 2010, Stagg et al, 2011
PRR agonists Fu et al, 2015, Corrales et al, 2015, Charlebois et al, 2017, Kranz et al 2016, Shekarian et al, 2017
Oncolytic viruses Ribas et al, 2017
Endogenous retroviruses DNMT inhibitors Chiappinelli et al, 2015; Roulois et al, 2015 Topper et al, 2017
HDAC inhibitors
CDK4/6 inhibitors Goel et al, 2017, Zhang et al, 2018
Costimulatory agonist CD40 agonist Byrne and Vonderheide, 2016